Renal cell carcinoma development and miRNAs: a possible link to the EGFR pathway

Papers of special note have been highlighted as: ▪ of interest ▪▪ of considerable interest

References

• 1  Ljungberg B, Campbell SC, Choi HY et al. The epidemiology of renal cell carcinoma. Eur. Urol.60(4),615–621 (2011).
  MedlineGoogle Scholar
• 2  Ljungberg B, Cowan NC, Hanbury DC et al. EAU guidelines on renal cell carcinoma: the 2010 update. Eur. Urol.58(3),398–406 (2010).
  MedlineGoogle Scholar
• 3  Bex A, Jonasch E, Kirkali Z et al. Integrating surgery with targeted therapies for renal cell carcinoma: current evidence and ongoing trials. Eur. Urol.58(6),819–828 (2010).
  MedlineGoogle Scholar
• 4  Eble JN, Sauter G, Epstein JI, Sesterhenn IA. Pathology and Genetics of Tumours of the Urinary System and Male Genital Organs. IARC Press, Lyon, France (2004).
  Google Scholar
• 5  Szymanska K, Moore LE, Rothman N et al. TP53, EGFR, and KRAS mutations in relation to VHL inactivation and lifestyle risk factors in renal-cell carcinoma from central and eastern Europe. Cancer Lett.293(1),92–98 (2010).
  Medline CASGoogle Scholar
• 6  Patard JJ, Pignot G, Escudier B et al. ICUD-EAU International Consultation on Kidney Cancer 2010: treatment of metastatic disease. Eur. Urol.60(4),684–690 (2011).
  MedlineGoogle Scholar
• 7  Staehler M, Haseke N, Schoeppler G, Stadler T, Gratzke C, Stief CG. Modern therapeutic approaches in metastatic renal cell carcinoma. EAU-EBU Update Series5(1),26–37 (2007).
  Google Scholar
• 8  Redova M, Svoboda M, Slaby O. MicroRNAs and their target gene networks in renal cell carcinoma. Biochem. Biophys. Res. Commun.405(2),153–156 (2011).
  Medline CASGoogle Scholar
• 9  Chou A, Toon C, Pickett J, Gill AJ. von Hippel-Lindau syndrome. Front. Horm. Res.41,30–49 (2013).
  Medline CASGoogle Scholar
• 10  Kaelin WG Jr. The von Hippel-Lindau tumor suppressor gene and kidney cancer. Clin. Cancer Res.10(18 Pt 2),6290S–6295S (2004).
  Medline CASGoogle Scholar
• 11  Kondo K, Kaelin WG Jr. The von Hippel-Lindau tumor suppressor gene. Exp. Cell. Res.264(1),117–125 (2001).
  Medline CASGoogle Scholar
• 12  Pugh CW, Ratcliffe PJ. The von Hippel-Lindau tumor suppressor, hypoxia-inducible factor-1 (HIF-1) degradation, and cancer pathogenesis. Semin. Cancer Biol.13(1),83–89 (2003).
  Medline CASGoogle Scholar
• 13  Lee SJ, Lattouf JB, Xanthopoulos J, Linehan WM, Bottaro DP, Vasselli JR. von Hippel-Lindau tumor suppressor gene loss in renal cell carcinoma promotes oncogenic epidermal growth factor receptor signaling via Akt-1 and MEK-1. Eur. Urol.54(4),845–853 (2008).
  Medline CASGoogle Scholar
• 14  Devita VTL, Theodore S, Rosenberg, Steven A. Devita, Hellman & Rosenberg’s Cancer: Principles & Practice of Oncology. Lippincott Williams & Wilkins, PA, USA, 4–8 (2008).
  Google Scholar
• 15  Smaldone MC, Maranchie JK. Clinical implications of hypoxia inducible factor in renal cell carcinoma. Urol. Oncol.27(3),238–245 (2009).
  Medline CASGoogle Scholar
• 16  Furniss D, Harden P, Ali N et al. Prognostic factors for renall cell carcinoma. Cancer Treat. Rev.34,407–426 (2008).
  Medline CASGoogle Scholar
• 17  Smith K, Gunaratnam L, Morley M. Silencing of epidermal growth factor receptor suppresses hypoxia-inducible factor-2 driven VHL^-/- renal cancer. Cancer Res.65(12),5221–5230 (2005).
  Medline CASGoogle Scholar
• 18  Mitsudomi T, Yatabe Y. Epidermal growth factor receptor in relation to tumor development: EGFR gene and cancer. FEBS J.277,301–308 (2009).▪ Reviews the discovery of EGFR, its signal transduction pathway and mutations.
  MedlineGoogle Scholar
• 19  Yarden Y, Sliwkowski MX. Untangling the ErbB signalling network. Nat. Rev. Mol. Cell. Biol.2(2),127–137 (2001).
  Medline CASGoogle Scholar
• 20  Olcay E, Giovannetti E, Peters G. Drug delivery and drug resistance: EGFR-tyrosine kinase inhibitors in non-small cell lung cancer. Open Lung Cancer J.3,26–33 (2010).
  CASGoogle Scholar
• 21  Liu W, Innocenti F, Wu M et al. A functional common polymorphism in a Sp1 recognition site of the epidermal growth factor receptor gene promoter. Cancer Res.65(1),46–53 (2005).
  Medline CASGoogle Scholar
• 22  Grandis J, Sok J. Signaling through the epidermal growth factor receptor during the development of malignancy. Pharmacol. Ther.102,37–46 (2004).
  Medline CASGoogle Scholar
• 23  Zhou L, Yang H. The von Hippel-Lindau tumor suppressor protein promotes c-Cbl-independent poly-ubiquitylation and degradation of the activated EGFR. PLoS ONE6(9),e23936 (2011).▪▪ Demonstrates that pVHL limits EGFR signaling by promoting c-Cbl-independent polyubiquitylation of the activated receptor, which likely results in its degradation by the proteosome.
  Medline CASGoogle Scholar
• 24  Wang Y, Roche O, Yan MS et al. Regulation of endocytosis via the oxygen-sensing pathway. Nat. Med.15(3),319–324 (2009).
  Medline CASGoogle Scholar
• 25  Shen J, Xia W, Khotskaya YB et al. EGFR modulates microRNA maturation in response to hypoxia through phosphorylation of AGO2. Nature497(7449),383–387 (2013).▪▪ First study to reveal a previously unrecognized function of EGFR in miRNA maturation and demonstrates how EGFR is likely to function as a regulator of AGO2 through novel post-translational modification.
  Medline CASGoogle Scholar
• 26  Ravaud A, Wallerand H, Culine S et al. Update on the medical treatment of metastatic renal cell carcinoma. Eur. Urol.54(2),315–325 (2008).
  Medline CASGoogle Scholar
• 27  Rini BI, Flaherty K. Clinical effect and future considerations for molecularly-targeted therapy in renal cell carcinoma. Urol. Oncol.26(5),543–549 (2008).
  Medline CASGoogle Scholar
• 28  Ravaud A, Gross-Goupil M. Overcoming resistance to tyrosine kinase inhibitors in renal cell carcinoma. Cancer Treat. Rev.38(8),996–1003 (2012).
  Medline CASGoogle Scholar
• 29  Gambari R, Fabbri E, Borgatti M et al. Targeting microRNAs involved in human diseases: a novel approach for modification of gene expression and drug development. Biochem. Pharmacol.82(10),1416–1429 (2011).
  Medline CASGoogle Scholar
• 30  Zhang J, Zhao H, Gao Y, Zhang W. Secretory miRNAs as novel cancer biomarkers. Biochim. Biophys. Acta1826(1),32–43 (2012).
  Medline CASGoogle Scholar
• 31  Jansson MD, Lund AH. MicroRNA and cancer. Mol. Oncol.6(6),590–610 (2012).
  Medline CASGoogle Scholar
• 32  Suzuki H, Maruyama R, Yamamoto E, Kai M. DNA methylation and microRNA dysregulation in cancer. Mol. Oncol.6(6),567–578 (2012).
  Medline CASGoogle Scholar
• 33  Pereira DM, Rodrigues PM, Borralho PM, Rodrigues CM. Delivering the promise of miRNA cancer therapeutics. Drug Discov. Today18(5–6),282–289 (2013).
  Medline CASGoogle Scholar
• 34  Kusenda B, Mraz M, Mayer J, Pospisilova S. MicroRNA biogenesis, functionality and cancer relevance. Biomed. Pap. Med. Fac. Univ. Palacky Olomouc Czech. Repub.150(2),205–215 (2006).
  Medline CASGoogle Scholar
• 35  Catto JW, Alcaraz A, Bjartell AS et al. MicroRNA in prostate, bladder, and kidney cancer: a systematic review. Eur. Urol.59(5),671–681 (2011).
  Medline CASGoogle Scholar
• 36  Chow TF, Youssef YM, Lianidou E et al. Differential expression profiling of microRNAs and their potential involvement in renal cell carcinoma pathogenesis. Clin. Biochem.43(1–2),150–158 (2010).
  Medline CASGoogle Scholar
• 37  Marques I, Teixeira AL, Ferreira M et al. Influence of survivin (BIRC5) and caspase-9 (CASP9) functional polymorphisms in renal cell carcinoma development: a study in a southern European population. Mol. Biol. Rep.40(8),4819–4826 (2013).
  Medline CASGoogle Scholar
• 38  Cho WC. MicroRNAs: potential biomarkers for cancer diagnosis, prognosis and targets for therapy. Int. J. Biochem. Cell Biol.42(8),1273–1281 (2010).
  Medline CASGoogle Scholar
• 39  Duns G, van den Berg A, van Dijk MC et al. The entire miR-200 seed family is strongly deregulated in clear cell renal cell cancer compared with the proximal tubular epithelial cells of the kidney. Genes Chromosomes Cancer52(2),165–173 (2012).
  MedlineGoogle Scholar
• 40  Cancer Genome Atlas Research Network. Comprehensive molecular characterization of clear cell renal cell carcinoma. Nature499(7456),43–49 (2013).▪ Recent publication giving a good overview and understanding of the molecular alterations of clear cell renal cell carcinoma.
  MedlineGoogle Scholar
• 41  Zhang H, Guo Y, Shang C, Song Y, Wu B. miR-21 downregulated TCF21 to inhibit KISS1 in renal cancer. Urology80(6),1298–1302 (2012).
  MedlineGoogle Scholar
• 42  Cho WC. OncomiRs: the discovery and progress of microRNAs in cancers. Mol. Cancer6,60 (2007).
  MedlineGoogle Scholar
• 43  Medina PP, Nolde M, Slack FJ. OncomiR addiction in an in vivo model of microRNA-21-induced pre-B-cell lymphoma. Nature467(7311),86–90 (2010).
  Medline CASGoogle Scholar
• 44  Fu X, Han Y, Wu Y et al. Prognostic role of microRNA-21 in various carcinomas: a systematic review and meta-analysis. Eur. J. Clin. Invest.41(11),1245–1253 (2011).
  Medline CASGoogle Scholar
• 45  Pan X, Wang ZX, Wang R. MicroRNA-21: a novel therapeutic target in human cancer. Cancer Biol. Ther.10(12),1224–1232 (2010).
  Medline CASGoogle Scholar
• 46  Liu LZ, Li C, Chen Q et al. MiR-21 induced angiogenesis through AKT and ERK activation and HIF-1α expression. PLoS ONE6(4),e19139 (2011).
  Medline CASGoogle Scholar
• 47  Zhou X, Ren Y, Moore L et al. Downregulation of miR-21 inhibits EGFR pathway and suppresses the growth of human glioblastoma cells independent of PTEN status. Lab. Invest.90(2),144–155 (2010).
  Medline CASGoogle Scholar
• 48  Bruning U, Cerone L, Neufeld Z et al. MicroRNA-155 promotes resolution of hypoxia-inducible factor 1alpha activity during prolonged hypoxia. Mol. Cell. Biol.31(19),4087–4096 (2011).
  Medline CASGoogle Scholar
• 49  Shinmei S, Sakamoto N, Goto K et al. MicroRNA-155 is a predictive marker for survival in patients with clear cell renal cell carcinoma. Int. J. Urol.20(5),468–477 (2013).
  Medline CASGoogle Scholar
• 50  Juan D, Alexe G, Antes T et al. Identification of a microRNA panel for clear-cell kidney cancer. Urology75(4),835–841 (2010).
  MedlineGoogle Scholar
• 51  Valera VA, Walter BA, Linehan WM, Merino MJ. Regulatory effects of microRNA-92 (miR-92) on VHL gene expression and the hypoxic activation of miR-210 in clear cell renal cell carcinoma. J. Cancer2,515–526 (2011).
  Medline CASGoogle Scholar
• 52  Chan SY, Loscalzo J. MicroRNA-210: a unique and pleiotropic hypoxamir. Cell Cycle9(6),1072–1083 (2010).
  Medline CASGoogle Scholar
• 53  Zhao A, Li G, Peoc’h M, Genin C, Gigante M. Serum miR-210 as a novel biomarker for molecular diagnosis of clear cell renal cell carcinoma. Exp. Mol. Pathol.94(1),115–120 (2013).
  Medline CASGoogle Scholar
• 54  Zhang C, Zhang J, Hao J et al. High level of miR-221/222 confers increased cell invasion and poor prognosis in glioma. J. Transl. Med.10(1),119 (2012).
  Medline CASGoogle Scholar
• 55  Garofalo M, Di Leva G, Romano G et al. miR-221 and 222 regulate TRAIL resistance and enhance tumorigenicity through PTEN and TIMP3 downregulation. Cancer Cell16(6),498–509 (2009).
  Medline CASGoogle Scholar
• 56  Shah M, Calin G. MicroRNAs miR-221 and miR-222: a new level of regulation in aggressive breast cancer. Genome Med.3(8),56 (2011).
  MedlineGoogle Scholar
• 57  Teixeira AL, Gomes M, Medeiros R. EGFR signaling pathway and related-miRNAs in age-related diseases: the example of miR-221 and miR-222. Front. Genet.3(286),7 (2012).
  MedlineGoogle Scholar
• 58  Wulfken LM, Moritz R, Ohlmann C et al. MicroRNAs in renal cell carcinoma: diagnostic implications of serum miR-1233 levels. PLoS ONE6(9),e25787 (2011).
  Medline CASGoogle Scholar
• 59  Ravi R, Mookerjee B, Bhujwalla ZM et al. Regulation of tumor angiogenesis by p53-induced degradation of hypoxia-inducible factor 1alpha. Genes Dev.14(1),34–44 (2000).
  Medline CASGoogle Scholar
• 60  Lou JJ, Chua YL, Chew EH, Gao J, Bushell M, Hagen T. Inhibition of hypoxia-inducible factor-1alpha (HIF-1alpha) protein synthesis by DNA damage inducing agents. PLoS ONE5(5),e10522 (2010).
  MedlineGoogle Scholar
• 61  Redova M, Poprach A, Nekvindova J et al. Circulating miR-378 and miR-451 in serum are potential biomarkers for renal cell carcinoma. J. Transl. Med.10,55 (2012).
  Medline CASGoogle Scholar
• 62  Teixeira AL, Silva J, Ferreira M et al. Circulating microRNA-222 in plasma – a potencial biomarker for renal cell carcinoma. Eur. J. Cancer48(Suppl. 5),S216 (2012).
  Google Scholar
• 63  Wettersten HI, Weiss RH. Potential biofluid markers and treatment targets for renal cell carcinoma. Nat. Rev. Urol.10(6),336–344 (2013).
  Medline CASGoogle Scholar
• 64  Jung M, Mollenkopf HJ, Grimm C et al. MicroRNA profiling of clear cell renal cell cancer identifies a robust signature to define renal malignancy. J. Cell. Mol. Med.13(9B),3918–3928 (2009).▪ Demonstrates that malignant and nonmalignant tissue can clearly be differentiated by their miRNA profile.
  MedlineGoogle Scholar
• 65  Koturbash I, Zemp FJ, Pogribny I, Kovalchuk O. Small molecules with big effects: the role of the microRNAome in cancer and carcinogenesis. Mutat. Res.722(2),94–105 (2011).
  Medline CASGoogle Scholar
• 66  Youssef YM, White NM, Grigull J et al. Accurate molecular classification of kidney cancer subtypes using microRNA signature. Eur. Urol.59(5),721–730 (2011).▪ Demonstrates that miRNA expression patterns can distinguish between renal cell carcinoma subtypes.
  Medline CASGoogle Scholar
• 67  Ma L. Role of miR-10b in breast cancer metastasis. Breast Cancer Res.12(5),26 (2010).
  Google Scholar
• 68  Park JK, Kogure T, Nuovo GJ et al. miR-221 silencing blocks hepatocellular carcinoma and promotes survival. Cancer Res.71(24),7608–7616 (2011).
  Medline CASGoogle Scholar
• 69  Kota J, Chivukula RR, O’Donnell KA et al. Therapeutic microRNA delivery suppresses tumorigenesis in a murine liver cancer model. Cell137(6),1005–1017 (2009).
  Medline CASGoogle Scholar
• 101  GeneCards^®. www.genecards.org (Accessed 1 March 2013)
  Google Scholar